NutriDex

The Supplement Research Compendium
🦠

Multi-strain Probiotics (general)

Mixed Lactobacillus + Bifidobacterium blends

Mixed Lactobacillus + Bifidobacterium blends for gut and antibiotic-related conditions

Strong evidence 🦠Probiotics🛡️Gut & Immune

✚ Updated · How we grade evidence

Evidence tier
Strong
Research weight
Citations
13 verified / 13
Classification
Probiotics
❝
What the evidence says. Multiple high-quality RCTs / meta-analyses with consistent effects.

What is Multi-strain Probiotics (general)?

Multi-strain Probiotics (general) (Mixed Lactobacillus + Bifidobacterium blends) is a probiotic strain used for prevents clostridioides difficile-associated diarrhea in adults/children on antibiotics (~60% relative risk reduction; greatest in higher-risk patients). NutriDex grades the human evidence as Strong. Multi-strain Lactobacillus + Bifidobacterium blends have their strongest, most consistent evidence in preventing antibiotic-associated and Clostridioides difficile-associated diarrhea: a 2017 Cochrane review of 39 RCTs (9,955 participants) found probiotics cut C. difficile diarrhea risk by ~60% (RR 0.40), with the benefit concentrated in higher-baseline-risk patients. Specific high-potency 8-strain formulations (the De Simone formulation, formerly VSL#3) have RCT-grade support for inducing remission in mild-to-moderate ulcerative colitis and maintaining remission in pouchitis. Effects are strain- and formulation-specific — not all blends are equally effective, and certainty for IBS from combination products is low. Multiple-strain preparations also appear most effective for preventing necrotizing enterocolitis in preterm infants.

Purported Benefits

✓Prevents Clostridioides difficile-associated diarrhea in adults/children on antibiotics (~60% relative risk reduction; greatest in higher-risk patients)
✓Reduces antibiotic-associated diarrhea; two-strain Lactobacillus+Bifidobacterium mixtures show RR ~0.51
✓Induces and maintains remission in mild-to-moderate ulcerative colitis (8-strain De Simone/VSL#3 formulation)
✓Maintains remission of recurrent/refractory pouchitis (85% vs 6% placebo at 1 year, De Simone formulation)
✓Reduces necrotizing enterocolitis and mortality in preterm infants (multi-strain blends rank most effective)
✓Improves H. pylori eradication rates and reduces eradication-therapy adverse events as adjunct to triple/quadruple therapy

Evidence by outcome

The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.

OutcomeEvidenceEffectStudies
Prevents C. difficile-associated diarrhea on antibioticsCochrane (39 RCTs) ~60% risk reduction; benefit concentrated in patients with >5% baseline risk. Strong ↑ benefit · large 2
Reduces antibiotic-associated diarrheaMeta-analysis of 19 RCTs; two-strain mixtures RR ~0.51, though not all mixtures effective. Strong ↑ benefit · moderate 1
Induces/maintains remission in UC and pouchitis (8-strain De Simone)RCT-grade support but specific to the high-dose De Simone formulation, not blends generally. Strong ↑ benefit · large 2
Reduces necrotizing enterocolitis and mortality in preterm infantsNetwork meta-analysis (25 trials) ranks multi-strain most effective; heterogeneous products. Moderate ↑ benefit · moderate 1
Improves global IBS symptoms (combination products)Strain/outcome meta-analysis rates combination-probiotic IBS benefit low/very-low certainty. Preliminary ↔ mixed · small 1

Dosing & Compounds

Typical Dose
For AAD/CDAD prevention: ~10-50 billion CFU/day, started within 1-2 days of the antibiotic and continued throughout (and a few days after) the course. For ulcerative colitis/pouchitis (De Simone formulation): high dose 3.6 trillion CFU twice daily (induction) or 6 g (~900 billion CFU) once daily (maintenance). Take with or near a meal.
Active Compounds
De Simone formulation (formerly VSL#3; now Visbiome) - 8 strains: 4 Lactobacillus, 3 Bifidobacterium, Streptococcus thermophilusTwo-strain Lactobacillus + Bifidobacterium animalis subsp. lactis blendsLyophilized (freeze-dried) capsules, sachets, and powdersHigh-CFU sachets (e.g., 450-900 billion CFU per dose for IBD use)

Safety & Cautions

Generally well tolerated in immunocompetent people; trial adverse-event rates are similar to placebo (mild gas/bloating most common). Caution or avoid in critically ill, immunocompromised, central venous catheter, short-gut, or post-surgical patients — rare bacteremia/sepsis and translocation have been reported, and a probiotic was linked to increased mortality in one severe acute pancreatitis RCT. Product quality and viable CFU vary between brands; effects do not transfer between different strain blends. Educational only — always check with your doctor or pharmacist before combining Multi-strain Probiotics (general) with any medicine.

Key Studies ★ 13 studies

Systematic review Ye 2026 ✓ PubMed
Systematic review and network meta-analysis comparing probiotic strains and preparations for preventing acute otitis media in children.
Systematic review Na 2026 ✓ PubMed
Network meta-analysis of probiotics' comparative efficacy and safety for respiratory tract infections in children.
Cochrane review Cochrane (Esmaeilinezhad) 2025 ✓ PubMed
Updated Cochrane review (search to March 2025): in participants at >5% baseline CDAD risk, probiotics cut CDAD from 11.6% (control) to 3.1% (probiotic) (13 trials, 2454 participants; ~70% relative reduction, NNT=12, moderate certainty).
Systematic review Cochrane plain-language summary 2025 ✓ Full text
In people prescribed antibiotics without a weakened immune system, short-term probiotics may offer a small benefit in preventing CDAD and are likely not harmful; large trials in low-risk populations are still needed.
Systematic review / meta-analysis Goyal A et al. 2021 (Lancet eClinicalMedicine) ✓ Source
Strain- and outcome-specific meta-analysis of IBS found efficacy for select single strains but low/very-low certainty of benefit for combination (multi-strain) probiotics on global IBS symptoms.
Cochrane systematic review / meta-analysis Goldenberg JZ et al. 2017 (Cochrane) ✓ Full text
In 39 RCTs (9,955 participants), probiotics reduced C. difficile-associated diarrhea risk by ~60% (RR 0.40, 95% CI 0.30-0.52); benefit was significant only in patients with >5% baseline CDAD risk.
Systematic review / meta-analysis McFarland LV et al. 2016 ✓ Full text
Meta-analysis of 19 RCTs (n=2,730) found some multi-strain probiotic mixtures significantly reduced antibiotic-associated diarrhea, with two-strain mixtures showing RR 0.51 (95% CI 0.38-0.68); not all mixtures were effective.
Systematic review with network meta-analysis Sniffen JC / McFarland LV et al. 2018 ✓ Full text
Network/systematic review showed effects are strain- and product-specific, with several Lactobacillus+Bifidobacterium combinations effective for AAD prevention while others showed no benefit.
Systematic review / network meta-analysis Chang HY et al. 2017 (PLOS One) ✓ Source
Updated meta-analysis (25 trials, 7,345 preterm infants) found multiple-strain probiotics ranked most effective for preventing necrotizing enterocolitis and reducing all-cause mortality.
Randomized controlled trial Tursi A et al. 2010 ✓ Full text
RCT in mild-to-moderate ulcerative colitis: VSL#3 (3.6 trillion CFU twice daily) plus standard therapy achieved >50% UCDAI improvement in 32.5% vs 10% on placebo at week 6.
Randomized double-blind controlled trial Mimura T et al. 2004 (Gut) ✓ PubMed
In recurrent/refractory pouchitis, once-daily high-dose VSL#3 maintained remission at 1 year in 85% vs 6% on placebo (p<0.0001); 36 patients randomized.
Review Carlone 2026 ✓ PubMed
Review of gut-microbiome-based strategies for supporting recovery in elite athletes.
Review Cheng 2026 ✓ PubMed
Efficacy of Lactobacillus plantarum on Body Composition, Lipid Profile, Liver Enzymes, and Inflammatory Markers in Overweight or Obese Adults: A GRADE Systematic Review and Meta-analysis of Randomized Trials
13 sources cited · 13 verified Search all studies on PubMed ↗

Common questions about Multi-strain Probiotics (general)

What is Multi-strain Probiotics (general) used for?

Multi-strain Probiotics (general) is most often taken for Prevents Clostridioides difficile-associated diarrhea in adults/children on antibiotics (~60% relative risk reduction; greatest in higher-risk patients), Reduces antibiotic-associated diarrhea; two-strain Lactobacillus+Bifidobacterium mixtures show RR ~0.51, Induces and maintains remission in mild-to-moderate ulcerative colitis (8-strain De Simone/VSL#3 formulation), Maintains remission of recurrent/refractory pouchitis (85% vs 6% placebo at 1 year, De Simone formulation). Mixed Lactobacillus + Bifidobacterium blends for gut and antibiotic-related conditions

Does Multi-strain Probiotics (general) work — what does the evidence say?

Strong evidence. Multiple high-quality RCTs / meta-analyses with consistent effects. Multi-strain Lactobacillus + Bifidobacterium blends have their strongest, most consistent evidence in preventing antibiotic-associated and Clostridioides difficile-associated diarrhea: a 2017 Cochrane review of 39 RCTs (9,955 participants) found probiotics cut C. difficile diarrhea risk by ~60% (RR 0.40), with the benefit concentrated in higher-baseline-risk patients. Specific high-potency 8-strain formulations (the De Simone formulation, formerly VSL#3) have RCT-grade support for inducing remission in mild-to-moderate ulcerative colitis and maintaining remission in pouchitis. Effects are strain- and formulation-specific — not all blends are equally effective, and certainty for IBS from combination products is low. Multiple-strain preparations also appear most effective for preventing necrotizing enterocolitis in preterm infants.

What is the typical dose of Multi-strain Probiotics (general)?

For AAD/CDAD prevention: ~10-50 billion CFU/day, started within 1-2 days of the antibiotic and continued throughout (and a few days after) the course. For ulcerative colitis/pouchitis (De Simone formulation): high dose 3.6 trillion CFU twice daily (induction) or 6 g (~900 billion CFU) once daily (maintenance). Take with or near a meal.

Is Multi-strain Probiotics (general) safe? Any cautions or side effects?

Generally well tolerated in immunocompetent people; trial adverse-event rates are similar to placebo (mild gas/bloating most common). Caution or avoid in critically ill, immunocompromised, central venous catheter, short-gut, or post-surgical patients — rare bacteremia/sepsis and translocation have been reported, and a probiotic was linked to increased mortality in one severe acute pancreatitis RCT. Product quality and viable CFU vary between brands; effects do not transfer between different strain blends.

How many studies support Multi-strain Probiotics (general)?

NutriDex cites 13 sources for Multi-strain Probiotics (general), graded "Strong".

Cite this page
APA

Peh, D. (2026). Multi-strain Probiotics (general) (Mixed Lactobacillus + Bifidobacterium blends): Benefits, Dosage, Side Effects & Evidence. NutriDex — The Supplement Research Compendium. Retrieved 16 Sept 2026, from https://nutridex.info/s/multi-strain

BibTeX
@misc{nutridex_multi_strain,
  author       = {Peh, Daryl},
  title        = {Multi-strain Probiotics (general) (Mixed Lactobacillus + Bifidobacterium blends): Benefits, Dosage, Side Effects \& Evidence},
  year         = {2026},
  howpublished = {NutriDex --- The Supplement Research Compendium},
  url          = {https://nutridex.info/s/multi-strain},
  note         = {Reviewed by Dr Daryl Peh, MBBS Singapore, MMed FM. Accessed 2026-09-16}
}

For medical claims, citing the underlying primary studies linked above is preferred. NutriDex is an educational reference, not medical advice.

← Back to the full dex · All substances